Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tongqiao Biyan Pian is a traditional Chinese patent medicine (TCM) formulated as an oral tablet for the treatment of various forms of rhinitis, including allergic rhinitis. Developed and manufactured by Yunnan Yongzitang (a subsidiary of Hunan Hansen Pharmaceutical), the medication is composed of a complex blend of herbal ingredients such as *Astragalus membranaceus*, *Atractylodes*, *Saposhnikovia divaricata* (Fangfeng), *Asarum*, and *Xanthium*. It is clinically used to relieve symptoms such as nasal congestion, sneezing, and runny nose. While it does not have a single defined molecular target, research indicates that it functions through multi-pathway modulation of inflammatory responses, potentially involving the PI3K/AKT signaling pathway and the regulation of inflammatory mediators.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Tongqiao Biyan Pian.